Koninklijke DSM N.V. Logo

Koninklijke DSM N.V.

DSM.AS

(1.2)
Stock Price

114,05 EUR

-9.23% ROA

1.82% ROE

41.64x PER

Market Cap.

763.733.544,00 EUR

28.13% DER

0% Yield

4.3% NPM

Koninklijke DSM N.V. Stock Analysis

Koninklijke DSM N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Koninklijke DSM N.V. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (28%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

ROE in an average range (4.89%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 PBV

The stock's PBV ratio (1.96x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

4 Buffet Intrinsic Value

The company's stock seems undervalued (1.762) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

5 ROA

The stock's ROA (-9.23%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Koninklijke DSM N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Koninklijke DSM N.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Koninklijke DSM N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Koninklijke DSM N.V. Revenue
Year Revenue Growth
1998 6.361.000.000
1999 6.333.000.000 -0.44%
2000 8.090.000.000 21.72%
2001 7.970.000.000 -1.51%
2002 6.665.000.000 -19.58%
2003 6.050.000.000 -10.17%
2004 7.879.000.000 23.21%
2005 8.195.000.000 3.86%
2006 8.380.000.000 2.21%
2007 8.757.000.000 4.31%
2008 9.297.000.000 5.81%
2009 8.322.000.000 -11.72%
2010 9.050.000.000 8.04%
2011 9.048.000.000 -0.02%
2012 9.131.000.000 0.91%
2013 9.051.000.000 -0.88%
2014 9.181.000.000 1.42%
2015 7.722.000.000 -18.89%
2016 7.920.000.000 2.5%
2017 8.632.000.000 8.25%
2018 9.267.000.000 6.85%
2019 9.010.000.000 -2.85%
2020 8.106.000.000 -11.15%
2021 9.204.000.000 11.93%
2022 8.550.000.000 -7.65%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Koninklijke DSM N.V. Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 338.000.000 100%
2011 378.000.000 10.58%
2012 381.000.000 0.79%
2013 351.000.000 -8.55%
2014 322.000.000 -9.01%
2015 330.000.000 2.42%
2016 309.000.000 -6.8%
2017 334.000.000 7.49%
2018 348.000.000 4.02%
2019 349.000.000 0.29%
2020 398.000.000 12.31%
2021 323.000.000 -23.22%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Koninklijke DSM N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 1.352.000.000 100%
2006 1.332.000.000 -1.5%
2007 0 0%
2008 1.466.000.000 100%
2009 1.532.000.000 4.31%
2010 380.000.000 -303.16%
2011 487.000.000 21.97%
2012 492.000.000 1.02%
2013 458.000.000 -7.42%
2014 476.000.000 3.78%
2015 512.000.000 7.03%
2016 552.000.000 7.25%
2017 524.000.000 -5.34%
2018 530.000.000 1.13%
2019 525.000.000 -0.95%
2020 469.000.000 -11.94%
2021 517.000.000 9.28%
2022 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Koninklijke DSM N.V. EBITDA
Year EBITDA Growth
1998 1.056.000.000
1999 1.012.000.000 -4.35%
2000 1.254.000.000 19.3%
2001 1.042.000.000 -20.35%
2002 450.000.000 -131.56%
2003 793.000.000 43.25%
2004 972.000.000 18.42%
2005 1.330.000.000 26.92%
2006 1.262.000.000 -5.39%
2007 1.241.000.000 -1.69%
2008 1.309.000.000 5.19%
2009 1.187.000.000 -10.28%
2010 816.000.000 -45.47%
2011 1.451.000.000 43.76%
2012 1.101.000.000 -31.79%
2013 1.268.000.000 13.17%
2014 1.176.000.000 -7.82%
2015 1.069.000.000 -10.01%
2016 1.127.000.000 5.15%
2017 1.314.000.000 14.23%
2018 1.733.000.000 24.18%
2019 1.517.000.000 -14.24%
2020 1.402.000.000 -8.2%
2021 1.710.000.000 18.01%
2022 1.345.000.000 -27.14%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Koninklijke DSM N.V. Gross Profit
Year Gross Profit Growth
1998 1.056.000.000
1999 1.012.000.000 -4.35%
2000 1.254.000.000 19.3%
2001 1.042.000.000 -20.35%
2002 588.000.000 -77.21%
2003 6.050.000.000 90.28%
2004 7.879.000.000 23.21%
2005 3.857.000.000 -104.28%
2006 3.826.000.000 -0.81%
2007 3.964.000.000 3.48%
2008 4.313.000.000 8.09%
2009 4.363.000.000 1.15%
2010 2.452.000.000 -77.94%
2011 2.521.000.000 2.74%
2012 2.412.000.000 -4.52%
2013 2.486.000.000 2.98%
2014 2.403.000.000 -3.45%
2015 2.451.000.000 1.96%
2016 2.658.000.000 7.79%
2017 2.933.000.000 9.38%
2018 3.405.000.000 13.86%
2019 3.053.000.000 -11.53%
2020 2.776.000.000 -9.98%
2021 3.164.000.000 12.26%
2022 2.528.000.000 -25.16%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Koninklijke DSM N.V. Net Profit
Year Net Profit Growth
1998 415.000.000
1999 371.000.000 -11.86%
2000 580.000.000 36.03%
2001 1.415.000.000 59.01%
2002 1.188.000.000 -19.11%
2003 139.000.000 -754.68%
2004 262.000.000 46.95%
2005 520.000.000 49.62%
2006 552.000.000 5.8%
2007 434.000.000 -27.19%
2008 571.000.000 23.99%
2009 337.000.000 -69.44%
2010 487.000.000 30.8%
2011 814.000.000 40.17%
2012 288.000.000 -182.64%
2013 271.000.000 -6.27%
2014 145.000.000 -86.9%
2015 88.000.000 -64.77%
2016 621.000.000 85.83%
2017 1.769.000.000 64.9%
2018 1.077.000.000 -64.25%
2019 758.000.000 -42.08%
2020 506.000.000 -49.8%
2021 747.000.000 32.26%
2022 368.000.000 -102.99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Koninklijke DSM N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 2
1999 2 -100%
2000 3 50%
2001 7 71.43%
2002 6 -16.67%
2003 1 0%
2004 1 100%
2005 3 50%
2006 3 0%
2007 2 0%
2008 3 33.33%
2009 2 -50%
2010 3 33.33%
2011 5 25%
2012 2 -300%
2013 2 0%
2014 1 0%
2015 0 0%
2016 4 100%
2017 10 70%
2018 6 -66.67%
2019 4 -50%
2020 3 -100%
2021 4 50%
2022 2 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Koninklijke DSM N.V. Free Cashflow
Year Free Cashflow Growth
1998 807.000.000
1999 610.000.000 -32.3%
2000 883.000.000 30.92%
2001 762.000.000 -15.88%
2002 650.000.000 -17.23%
2003 158.000.000 -311.39%
2004 899.000.000 82.42%
2005 300.000.000 -199.67%
2006 172.000.000 -74.42%
2007 391.000.000 56.01%
2008 319.000.000 -22.57%
2009 819.000.000 61.05%
2010 687.000.000 -19.21%
2011 405.000.000 -69.63%
2012 44.000.000 -820.45%
2013 154.000.000 71.43%
2014 155.000.000 0.65%
2015 153.000.000 -1.31%
2016 523.000.000 70.75%
2017 441.000.000 -18.59%
2018 698.000.000 36.82%
2019 744.000.000 6.18%
2020 868.000.000 14.29%
2021 850.000.000 -2.12%
2022 160.500.000 -429.6%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Koninklijke DSM N.V. Operating Cashflow
Year Operating Cashflow Growth
1998 811.000.000
1999 651.000.000 -24.58%
2000 900.000.000 27.67%
2001 764.000.000 -17.8%
2002 658.000.000 -16.11%
2003 591.000.000 -11.34%
2004 911.000.000 35.13%
2005 693.000.000 -31.46%
2006 630.000.000 -10%
2007 825.000.000 23.64%
2008 910.000.000 9.34%
2009 1.276.000.000 28.68%
2010 1.103.000.000 -15.68%
2011 882.000.000 -25.06%
2012 730.000.000 -20.82%
2013 889.000.000 17.89%
2014 808.000.000 -10.02%
2015 696.000.000 -16.09%
2016 1.018.000.000 31.63%
2017 996.000.000 -2.21%
2018 1.391.000.000 28.4%
2019 1.385.000.000 -0.43%
2020 1.494.000.000 7.3%
2021 1.427.000.000 -4.7%
2022 333.000.000 -328.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Koninklijke DSM N.V. Capital Expenditure
Year Capital Expenditure Growth
1998 4.000.000
1999 41.000.000 90.24%
2000 17.000.000 -141.18%
2001 2.000.000 -750%
2002 8.000.000 75%
2003 433.000.000 98.15%
2004 12.000.000 -3508.33%
2005 393.000.000 96.95%
2006 458.000.000 14.19%
2007 434.000.000 -5.53%
2008 591.000.000 26.57%
2009 457.000.000 -29.32%
2010 416.000.000 -9.86%
2011 477.000.000 12.79%
2012 686.000.000 30.47%
2013 735.000.000 6.67%
2014 653.000.000 -12.56%
2015 543.000.000 -20.26%
2016 495.000.000 -9.7%
2017 555.000.000 10.81%
2018 693.000.000 19.91%
2019 641.000.000 -8.11%
2020 626.000.000 -2.4%
2021 577.000.000 -8.49%
2022 172.500.000 -234.49%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Koninklijke DSM N.V. Equity
Year Equity Growth
1998 2.238.000.000
1999 2.535.000.000 11.72%
2000 3.070.000.000 17.43%
2001 4.298.000.000 28.57%
2002 5.186.000.000 17.12%
2003 4.961.000.000 -4.54%
2004 4.834.000.000 -2.63%
2005 5.541.000.000 12.76%
2006 5.855.000.000 5.36%
2007 5.383.000.000 -8.77%
2008 4.695.000.000 -14.65%
2009 5.011.000.000 6.31%
2010 5.577.000.000 10.15%
2011 5.974.000.000 6.65%
2012 6.042.000.000 1.13%
2013 6.098.000.000 0.92%
2014 5.936.000.000 -2.73%
2015 5.631.000.000 -5.42%
2016 6.180.000.000 8.88%
2017 7.065.000.000 12.53%
2018 7.815.000.000 9.6%
2019 7.835.000.000 0.26%
2020 7.487.000.000 -4.65%
2021 9.397.000.000 20.33%
2022 10.105.000.000 7.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Koninklijke DSM N.V. Assets
Year Assets Growth
1998 5.860.000.000
1999 6.307.000.000 7.09%
2000 7.847.000.000 19.63%
2001 8.575.000.000 8.49%
2002 8.996.000.000 4.68%
2003 9.400.000.000 4.3%
2004 8.936.000.000 -5.19%
2005 10.025.000.000 10.86%
2006 10.091.000.000 0.65%
2007 9.828.000.000 -2.68%
2008 9.653.000.000 -1.81%
2009 9.614.000.000 -0.41%
2010 10.480.000.000 8.26%
2011 11.157.000.000 6.07%
2012 11.966.000.000 6.76%
2013 12.017.000.000 0.42%
2014 12.126.000.000 0.9%
2015 11.743.000.000 -3.26%
2016 12.958.000.000 9.38%
2017 12.802.000.000 -1.22%
2018 13.641.000.000 6.15%
2019 13.443.000.000 -1.47%
2020 14.364.000.000 6.41%
2021 16.013.000.000 10.3%
2022 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Koninklijke DSM N.V. Liabilities
Year Liabilities Growth
1998 3.622.000.000
1999 3.772.000.000 3.98%
2000 4.777.000.000 21.04%
2001 4.277.000.000 -11.69%
2002 3.810.000.000 -12.26%
2003 4.439.000.000 14.17%
2004 4.102.000.000 -8.22%
2005 4.484.000.000 8.52%
2006 4.236.000.000 -5.85%
2007 4.445.000.000 4.7%
2008 4.958.000.000 10.35%
2009 4.603.000.000 -7.71%
2010 4.903.000.000 6.12%
2011 5.183.000.000 5.4%
2012 5.924.000.000 12.51%
2013 5.919.000.000 -0.08%
2014 6.190.000.000 4.38%
2015 6.112.000.000 -1.28%
2016 6.778.000.000 9.83%
2017 5.737.000.000 -18.15%
2018 5.826.000.000 1.53%
2019 5.608.000.000 -3.89%
2020 6.877.000.000 18.45%
2021 6.616.000.000 -3.94%
2022 6.558.000.000 -0.88%

Koninklijke DSM N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
48.38
Net Income per Share
2.74
Price to Earning Ratio
41.64x
Price To Sales Ratio
0.09x
POCF Ratio
20.5
PFCF Ratio
2.38
Price to Book Ratio
1.96
EV to Sales
-0.24
EV Over EBITDA
-1.46
EV to Operating CashFlow
-2.06
EV to FreeCashFlow
-6.2
Earnings Yield
0.02
FreeCashFlow Yield
0.42
Market Cap
0,76 Bil.
Enterprise Value
-1,99 Bil.
Graham Number
59.93
Graham NetNet
-14.47

Income Statement Metrics

Net Income per Share
2.74
Income Quality
0.57
ROE
0.05
Return On Assets
0
Return On Capital Employed
-0.38
Net Income per EBT
0.78
EBT Per Ebit
0.24
Ebit per Revenue
0.23
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.3
Operating Profit Margin
0.23
Pretax Profit Margin
0.06
Net Profit Margin
0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.73
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
5.56
Free CashFlow per Share
1.85
Capex to Operating CashFlow
-0.67
Capex to Revenue
-0.08
Capex to Depreciation
0
Return on Invested Capital
0.12
Return on Tangible Assets
-0.09
Days Sales Outstanding
0
Days Payables Outstanding
90.35
Days of Inventory on Hand
149.78
Receivables Turnover
0
Payables Turnover
4.04
Inventory Turnover
2.44
Capex per Share
-3.71

Balance Sheet

Cash per Share
16,61
Book Value per Share
58,27
Tangible Book Value per Share
-67.5
Shareholders Equity per Share
58.27
Interest Debt per Share
15.89
Debt to Equity
0.28
Debt to Assets
0
Net Debt to EBITDA
-2.02
Current Ratio
3.15
Tangible Asset Value
-11,71 Bil.
Net Current Asset Value
1,57 Bil.
Invested Capital
0.28
Working Capital
5,55 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
1,41 Bil.
Average Inventory
2339000000
Debt to Market Cap
3.72

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Koninklijke DSM N.V. Dividends
Year Dividends Growth
2000 2
2001 2 0%
2002 2 0%
2003 2 0%
2004 2 0%
2005 2 0%
2006 2 0%
2007 2 50%
2008 1 -100%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 2 0%
2014 2 0%
2015 2 0%
2016 2 0%
2017 1 0%
2018 2 50%
2019 2 0%
2020 2 0%
2021 2 0%
2022 3 0%

Koninklijke DSM N.V. Profile

About Koninklijke DSM N.V.

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments. The Nutrition segment offers animal nutrition and health products, including vitamins, premixes, carotenoids, enzymes, microbes, and eubiotics; human nutrition and health products comprising vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics, and prebiotics, as well as active pharmaceutical ingredients; premix, market-ready solutions, and personalized nutrition; human milk oligosaccharides; and skin and sun care, hair care, and aroma ingredients; omega-3 fatty acids; and specialty food enzymes, cultures, bio-preservation, texturizing hydrocolloids, sugar reduction, and savory taste solutions. The Materials segment provides specialty plastics used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries; and Dyneema, a fiber solution for use in personal protection, workwear, sports apparel, outdoor equipment, ropes and slings, synthetic chains, and nets for the aquaculture, and renewable energy sectors. The Innovation Center segment offers biomedical materials, and medical device and material manufacturing technologies in the areas of cardiovascular, continence care, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, peripheral vascular, plastic and reconstructive surgery, and wound management. It also commercializes yeast technology yeast for ethanol production. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

CEO
Mr. Dimitri de Vreeze
Employee
19.263
Address
Het Overloon 1
Heerlen, 6411 TE

Koninklijke DSM N.V. Executives & BODs

Koninklijke DSM N.V. Executives & BODs
# Name Age
1 Mr. Dimitri de Vreeze
Co-Chief Executive Officer, Chief Operating Officer & Member of the Managing Board
70
2 Mr. Paul Gilgen
Head of Manufacturing & Purchasing of DSM Nutritional Products
70
3 Ms. Lieke de Jong-Tops
Senior Communications Mang.
70
4 Mr. Luca Rosetto
Senior Vice President of Operations - Nutritional Products
70
5 Mr. Bruno Müller
Head of Strategy & VITAL Project - Nutritional Products
70
6 Ms. Cristina Monteiro
Executive Vice President of People & Organization
70
7 Mr. Manfred Eggersdorfer
Senior Vice President of Nutrition Science & Advocacy
70
8 Mr. Rob J. Atsma
Head of Energie Beheer Nederland
70
9 Mr. Dave Huizing
Vice President of Investor Relations
70
10 Mr. Hugh C. Welsh
Gen. Counsel, Sec. & Pres of DSM North America
70
11 Mr. Atul Thakrar
Pres of Bio-Based Products & Services Unit
70
12 Mr. Jan Wolters
Head of Fine Chemicals
70
13 Ms. Geraldine Matchett
Co-Chief Executive Officer, Chief Financial Officer & Member of the Managing Board
70
14 Mr. Philip Eykerman
Pres of Food Specialties and Corporation Mergers & Acquisitions
70
15 Ms. Patricia Malarkey
Chief Innovation Officer
70

Koninklijke DSM N.V. Competitors

Akzo Nobel N.V. Logo
Akzo Nobel N.V.

AKZA.AS

(2.0)
Wolters Kluwer N.V. Logo
Wolters Kluwer N.V.

WKL.AS

(3.0)
Koninklijke Philips N.V. Logo
Koninklijke Philips N.V.

PHIA.AS

(1.2)
Randstad N.V. Logo
Randstad N.V.

RAND.AS

(2.5)
Koninklijke KPN N.V. Logo
Koninklijke KPN N.V.

KPN.AS

(2.0)